GlobeNewswire by notified

Bonduelle - Arrival of Xavier Unkovic as CEO of the Bonduelle Group

Share

BONDUELLE

A French SCA (Partnership Limited by Shares) with a capital of 57 102 699,50 Euros

Head Office: La Woestyne 59173 Renescure, France

Registered under number: 447 250 044 (Dunkerque Commercial and Companies Register)


Villeneuve d’Ascq, May 22nd2023

Arrival of Xavier Unkovic as CEO of the Bonduelle Group

The Bonduelle Group announces the appointment of Xavier Unkovic as Chief Executive Officer of the Group. This appointment will take effect on June 1, 2023.
Until that date, Christophe Bonduelle, Chairman of the Board of Directors, will be responsible for the Group's general management.

Christophe Bonduelle, non-executive Chairman of the Board of Directors, states :

« The Board of Directors and I are convinced that in the demanding environment in which the company is evolving, Xavier Unkovic will successfully lead the next stage of Bonduelle's profitable development. Xavier Unkovic held senior management positions in the United States for 23 years, first with the Mars Group and then with Amy's kitchen, which he turned around and developed. »

Xavier Unkovic states:

« I am honored to join and soon lead the Bonduelle Group. It is a company for which I have always had great admiration and respect for its pioneering and entrepreneurial spirit, its ambition and its mission. I look forward to working with all the employees, the Executive Committee and the Board, in close collaboration with the Chairman, to meet the challenges facing Bonduelle and to write the next chapter of the Group's development. »

Biographical details

Xavier Unkovic has 30 years of experience in the development of consumer goods businesses in the American, European and Asian markets. After starting his career in finance, sales and marketing, he became CEO of Royal Canin in the United States in 2000 and then in Canada in 2003. Xavier Unkovic then headed the Mars Group's Beverages division in 2010 for North America, and then for the world as of 2013. In 2017, he became President and CEO of Amy's Kitchen, a BCorp-certified californian company that markets a range of organic prepared meals. Since 2021, Xavier Unkovic has been the CEO of the French company NAOS, a major player in skin care and health, under the brands Bioderma, Institut Esthederm and Etat Pur.

About the Bonduelle Group:
We want to inspire the transition to plant-based food, to contribute to the well-being of Man and the preservation of the planet. We are a French family business with 12,000 employees and we have been innovating with our farming partners since 1853. Our ready-to-use products are grown on 70,000 hectares and marketed in 100 countries, with sales of €2,203 million. Our 4 brands are Bonduelle, Cassegrain, Globus and Ready Pac Bistro.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye